Literature DB >> 21183645

New insights into the genetic organization of the FK228 biosynthetic gene cluster in Chromobacterium violaceum no. 968.

Vishwakanth Y Potharla1, Shane R Wesener, Yi-Qiang Cheng.   

Abstract

The biosynthetic gene cluster of FK228, an FDA-approved anticancer natural product, was identified and sequenced previously. The genetic organization of this gene cluster has now been delineated through systematic gene deletion and transcriptional analysis. As a result, the gene cluster is redefined to contain 12 genes: depA through depJ, depM, and a newly identified pathway regulatory gene, depR.

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 21183645      PMCID： PMC3067218          DOI： 10.1128/AEM.01512-10

Source DB:  PubMed          Journal:  Appl Environ Microbiol        ISSN： 0099-2240            Impact factor:   4.792


  13 in total

1.  FK228 (depsipeptide) as a natural prodrug that inhibits class I histone deacetylases.

Authors:  Ryohei Furumai; Akihisa Matsuyama; Nobuyuki Kobashi; Kun-Hyung Lee; Makoto Nishiyama; Hidenori Nakajima; Akito Tanaka; Yasuhiko Komatsu; Norikazu Nishino; Minoru Yoshida; Sueharu Horinouchi
Journal:  Cancer Res       Date:  2002-09-01       Impact factor: 12.701

2.  A division inhibitor and a topological specificity factor coded for by the minicell locus determine proper placement of the division septum in E. coli.

Authors:  P A de Boer; R E Crossley; L I Rothfield
Journal:  Cell       Date:  1989-02-24       Impact factor: 41.582

Review 3.  Bacterial cell division: assembly, maintenance and disassembly of the Z ring.

Authors:  David W Adams; Jeff Errington
Journal:  Nat Rev Microbiol       Date:  2009-09       Impact factor: 60.633

4.  FR901228, a novel antitumor bicyclic depsipeptide produced by Chromobacterium violaceum No. 968. I. Taxonomy, fermentation, isolation, physico-chemical and biological properties, and antitumor activity.

Authors:  H Ueda; H Nakajima; Y Hori; T Fujita; M Nishimura; T Goto; M Okuhara
Journal:  J Antibiot (Tokyo)       Date:  1994-03       Impact factor: 2.649

5.  StatBite: FDA oncology drug product approvals in 2009.

Authors: 
Journal:  J Natl Cancer Inst       Date:  2010-02-09       Impact factor: 13.506

6.  Structural basis of the redox switch in the OxyR transcription factor.

Authors:  H Choi; S Kim; P Mukhopadhyay; S Cho; J Woo; G Storz; S E Ryu
Journal:  Cell       Date:  2001-04-06       Impact factor: 41.582

7.  Characterization of a gene cluster responsible for the biosynthesis of anticancer agent FK228 in Chromobacterium violaceum No. 968.

Authors:  Yi-Qiang Cheng; Min Yang; Andrea M Matter
Journal:  Appl Environ Microbiol       Date:  2007-03-30       Impact factor: 4.792

Review 8.  Assembly dynamics of the bacterial MinCDE system and spatial regulation of the Z ring.

Authors:  Joe Lutkenhaus
Journal:  Annu Rev Biochem       Date:  2007       Impact factor: 23.643

9.  FDA approval summary: vorinostat for treatment of advanced primary cutaneous T-cell lymphoma.

Authors:  Bhupinder S Mann; John R Johnson; Martin H Cohen; Robert Justice; Richard Pazdur
Journal:  Oncologist       Date:  2007-10

10.  A broad-host-range Flp-FRT recombination system for site-specific excision of chromosomally-located DNA sequences: application for isolation of unmarked Pseudomonas aeruginosa mutants.

Authors:  T T Hoang; R R Karkhoff-Schweizer; A J Kutchma; H P Schweizer
Journal:  Gene       Date:  1998-05-28       Impact factor: 3.688
View more
  13 in total

1.  Reconstitution of the FK228 biosynthetic pathway reveals cross talk between modular polyketide synthases and fatty acid synthase.

Authors:  Shane R Wesener; Vishwakanth Y Potharla; Yi-Qiang Cheng
Journal:  Appl Environ Microbiol       Date:  2010-12-23       Impact factor: 4.792

Review 2.  Microbial natural products: molecular blueprints for antitumor drugs.

Authors:  Lesley-Ann Giddings; David J Newman
Journal:  J Ind Microbiol Biotechnol       Date:  2013-09-03       Impact factor: 3.346

3.  Revised genome sequence of Burkholderia thailandensis MSMB43 with improved annotation.

Authors:  Ying Zhuo; Lin Liu; Qi Wang; Xiangyang Liu; Biao Ren; Mei Liu; Peixiang Ni; Yi-Qiang Cheng; Lixin Zhang
Journal:  J Bacteriol       Date:  2012-09       Impact factor: 3.490

4.  Thailandepsins: bacterial products with potent histone deacetylase inhibitory activities and broad-spectrum antiproliferative activities.

Authors:  Cheng Wang; Leonhard M Henkes; Leah B Doughty; Min He; Difei Wang; Franz-Josef Meyer-Almes; Yi-Qiang Cheng
Journal:  J Nat Prod       Date:  2011-07-27       Impact factor: 4.050

Review 5.  Genome-guided discovery of diverse natural products from Burkholderia sp.

Authors:  Xiangyang Liu; Yi-Qiang Cheng
Journal:  J Ind Microbiol Biotechnol       Date:  2013-11-09       Impact factor: 3.346

6.  Engineered Production of Tryprostatins in E. coli through Reconstitution of a Partial ftm Biosynthetic Gene Cluster from Aspergillus sp.

Authors:  Gopitkumar R Shah; Shane R Wesener; Yi-Qiang Cheng
Journal:  Jacobs J Biotechnol Bioeng       Date:  2014-12-18

7.  Identification and characterization of the spiruchostatin biosynthetic gene cluster enable yield improvement by overexpressing a transcriptional activator.

Authors:  Vishwakanth Y Potharla; Cheng Wang; Yi-Qiang Cheng
Journal:  J Ind Microbiol Biotechnol       Date:  2014-06-29       Impact factor: 3.346

8.  Origin and bioactivities of thiosulfinated FK228.

Authors:  Xiangyang Liu; Grant C Currens; Liang Xue; Yi-Qiang Cheng
Journal:  Medchemcomm       Date:  2019-03-25       Impact factor: 3.597

9.  Improved production of cytotoxic thailanstatins A and D through metabolic engineering of Burkholderia thailandensis MSMB43 and pilot scale fermentation.

Authors:  Xiangyang Liu; Hui Zhu; Sreya Biswas; Yi-Qiang Cheng
Journal:  Synth Syst Biotechnol       Date:  2016-04-01

10.  FK228 from Burkholderia thailandensis MSMB43.

Authors:  Xiang-Yang Liu; Cheng Wang; Yi-Qiang Cheng
Journal:  Acta Crystallogr Sect E Struct Rep Online       Date:  2012-08-23
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.